Abstract. The purpose of the present study was to investigate the role of latency-associated peptide (LAP) + CD4 + T cells in hepatocellular carcinoma (HCC) immunity. Flow cytometric analysis was performed to detect the proportion of LAP + CD4 + T cells among the peripheral blood mononuclear cells (PBMCs) of 30 HBV-infected HCC patients at the pre-operative and post-operative stages, as well as 30 hepatitis B virus (HBV)-infected volunteers as a control group. Furthermore, tumor tissues and peri-tumor tissues from 28 patients with HCC, as well as hepatic tissues from 28 HBV-infected patients with benign lesions were subjected to immunohistochemical analysis with double staining for LAP and CD4, and the average number of the LAP + CD4 + T cells in each visual field was quantified. The results indicated that the proportion of LAP+CD4+ T cells in the PBMCs of patients with HCC was significantly higher than that in the control group (1.84±0.85 vs. 0.73±0.39%, P= 0.019), while it was significantly reduced after the operation (1.07±0.35, P=0.021), but still slightly, if not significantly, higher compared with that in the control group (P= 0.342). Furthermore, the number of LAP + CD4 + T cells per high-magnification microscopic field (magnification, x400) in the HCC tissues was 11.25±3.00, which was significantly higher than that in the peri-cancer tissues (5.75±1.00) and that in the HBV-infected hepatic tissues around benign lesions (2.61±0.83). In peri-cancer tissues, LAP + CD4 + T cells were also significantly more abundant than in control tissues. Furthermore, in the HCC tissues, LAP + CD4 + T cells were present as clusters in the tumor stroma and closely associated with CD4 + T lymphocytes. By contrast, in the peri-cancer liver tissues and HBV-infected hepatic tissues around benign lesions, LAP + CD4 + T cells were sparsely distributed. LAP + CD4 + T cells have marked inhibitory effects, and in the peripheral blood and tumor tissues of patients with HCC, they have an important role in the suppression of anti-tumor immunity and in the immune evasion of tumor cells.
Introduction
T regulatory (Treg) cells are important suppressive immune regulatory cells that exert their immunosuppressive effects by producing cytokines with inhibitory functions and have an important role in the maintenance of immune homeostasis (1) . Treg cells facilitate immune evasion via two mechanisms: Immune anergy and immunosuppression; they reduce the recognition of tumor antigens by the organism, induce immune tolerance of tumor antigens associated with immune anergy and negatively regulate the anti-tumor immune response associated with immunosuppression, resulting in immune escape of malignancies (2) . Treg cells account for 5-10% of CD4 + T cells and may be divided into natural Treg (nTreg) cells and inducible Treg (iTreg) cells (3) . nTreg mainly refers to CD4 + CD25 + Treg cells and iTreg refers to transforming growth factor (TGF)-β-secreting T helper lymphocyte 3 (Th3) and IL-10-secreting type 1 regulatory T (Tr1) cells (4) (5) (6) . Furthermore, immunosuppressive CD8 + Treg and natural killer T cells, which exhibit bidirectional immunity, represent two categories of Tregs (7, 8 
Materials and methods
Clinical information. The pre-operative group included 30 patients with HCC who were preliminarily diagnosed at the department of Hepatobiliary and Laparoscopic Surgery, Shenzhen Hospital (Peking University, Shenzhen, China) between October 2011 and December 2012, including 17 males and 13 females at the age of 42-60 years (median age, 51.4 years). Patients exhibited a chronic hepatitis B virus (HBV) infection and did not receive any treatment (including transcatheter hepatic arterial chemoembolization) prior to surgery. They were diagnosed with HCC after post-operative pathological examination. The post-operative group comprised 28 patients with HCC from the pre-operative group (two patients were unable to undergo the surgery due to metastasis in other organs), including 16 males and 12 females (age range, 42-60 years; median age, 52.1 years). The peripheral blood control group included 30 HBV-carrying volunteers (16 males, 14 female; age range, 39-57 years; median age, 48.3 years) who presented at the aforementioned hospital with chronic cholecystitis, inguinal hernia and chronic appendicitis between October 2011 and December 2012. The histopathology control group contained 28 HBV-carrying patients who received hepatic resection due to benign lesions, including 16 males and 12 females (age range, 35-52 years; median age, 45.7 years). None of the patients included in the present study had diabetes, hyperthyroidism or any autoimmune diseases. The differences in gender and age between the HCC pre or post-operative group and the peripheral blood control group, and the differences between the HCC or peri-cancer group and the hepatic tissue control group were not statistically significant.
Sample collection. The blood specimens were collected using disposable vacuum blood collection tubes. Each sample contained 6 ml venous blood from the subject that was drawn in the morning after the subject had fasted. All specimens were processed within 4 h following collection and analyzed within 16 h. The blood samples were collected three days prior to the operation for the pre-operative group and 10 days after the operation for the post-operative group.
Fresh hepatic tissue was collected from patients after hepatectomy, fixed in formalin, embedded in conventional paraffin and continuously cut into 4-µm sections. Hepatic tumor samples and peri-cancer tissue samples (collected ≤2 cm away from the carcinoma nodule) were collected separately from patients with HCC, avoiding the necrotic region, and assigned to the HCC group and the hepatocellular peri-cancer group. For the control group, HBV-infected hepatic tissues around benign lesions were collected following hepatectomy due to benign lesions. The blood sample (3 ml) was diluted with an equal volume of PBS. The lymphocytes were isolated by mixing 3 ml sample with lymphocyte separation medium, followed by centrifugation at a speed of 500 x g for 20 min at 25˚C. The cells were re-suspended with 200 µl buffer and 100 µl of this lymphocyte suspension was added to Tube A (experimental tube) and Tube B (isotype tube), followed by addition of monoclonal CD4-FITC antibodies (1:5,000) to each tube. The samples were incubated for 20 min at 25˚C in the dark, fixed with 500 µl of 4% paraformaldehyde for 10 min at 25˚C and washed twice with PBS. LAP-PE mAb (10 µl; 1:5,000) was added to Tube A and isotype control IgG1-PE (10 µl; 1:5,000) was added to Tube B. The samples were incubated for 45 min at 25˚C in the dark. After one wash with PBS, the lymphocytes were re-suspended in 500 µl PBS and analyzed with the four-color flow cytometer. At least 50,000 lymphocytes were collected for each acquisition. Flow jo software (flowjo 7.6.1; BD Biosciences) was used to analyze the results.
Analysis of LAP

Analysis of LAP + CD4 + T cells in HCC tissue by immunohistochemical staining with double enzyme labeling.
As the major reagents, goat anti-human LAP polyclonal antibody (cat. no. AF-246-NA) was purchased from R & D Systems and was diluted at 1:100 for use furthermore, ready-to use rabbit anti-human CD4 mAb (cat. no. YB-0766R), enzyme-labeled rabbit anti-goat IgG (cat. no. EHJSW-135238), streptavidin-peroxidase (cat. no. SP KIT-D1), 3-amino-9-ethylcarbazole (AEC) color reagent kit (cat. no. HPBIO-JC583), and diaminobenzidine (DAB) color reagent kit (cat. no. YYJK-1009) were purchased from Fuzhou Maixin (Fuzhou, Fujian, China).
The tissue sections were de-waxed, incubated with pepsin (1:10,000; cat. no. P7012-250MG; Sigma-Aldrich; Merck KGaA) in a 37˚C incubator for 25 min, washed with PBS and then soaked in 3% H 2 O 2 for 20 min at room temperature. Samples were further washed with PBS twice for 5 min, to discard the H 2 O 2 solution and then 10% fetal calf serum (cat. no. KL-P0015; Sigma-Aldrich; Merck KGaA) was added and the samples were incubated in a 37˚C incubator for 30 min. Ready-to use rabbit anti-human CD4 monoclonal antibody (1:100) was added and the samples were incubated at 4˚C overnight. After being washed with PBS, the samples were incubated with enzyme-labeled rabbit anti-goat IgG (1:100) in a 37˚C incubator for 30 min. After washing with PBS, streptavidin-peroxidase was added and the samples were incubated in a 37˚C incubator for 30 min. The samples were then washed with PBS, followed by incubation coloration with DAB for 4 min at 25˚C and soaking in 3% H 2 O 2 for 20 min at room temperature. After another wash with PBS, the samples were incubated with 10% fetal calf serum in a 37˚C incubator for 30 min. Subsequently, the samples were incubated with goat anti-human LAP polyclonal antibody at a dilution of 1:100 at 4˚C overnight. The samples were washed with PBS and incubated with enzyme-labeled rabbit anti-goat IgG (1:100) in a 37˚C incubator for 30 min. After another wash with PBS, the samples were incubated with streptavidin-peroxidase in a 37˚C incubator for 30 min. After being washed with PBS, the samples were incubated with AEC for 4 min to visualize the antibodies. Subsequently, the samples were dehydrated, cleared, sealed and examined under a microscope. LAP + CD4 + T cells were identified as follows: Complete cellular morphology, clear structure, brown/yellow and purple/red granules specifically co-localized in the cytoplasm and on cell the membrane (brown granules). CD4 + T cells were identified as follows: Complete morphology, clear structure, brown/yellow granules specifically located in the cytoplasm and on the cell membrane. The slides were observed under a microscope by an observer blinded to the sample identity. First, the whole slide was observed at a low magnification. Subsequently, 5 high-power fields (magnification, x400) were randomly selected for quantification of stained cells and calculation of the mean value.
Statistical analysis. Values are expressed as the mean ± standard deviation of the percentage. A paired Student's t-test was used for comparisons between HCC and corresponding peri-cancer samples, as well as between HCC pre-operative peripheral blood samples and their corresponding post-operative samples. Two-way analysis of variance was performed for multi-group comparisons involving the control and the HCC groups, and Tukey's post-hoc test was used for comparisons between the control and the HCC groups (peripheral blood control group vs. pre/post-operative group for FCM results and hepatic tissue control group vs. HCC/peri-cancer group for immunohistochemistry results). SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for data processing. P<0.05 was considered to indicate a statistically significant difference. of the HCC pre-operative group was significantly higher than that in the control group (P=0.019). Table I , the proportion of LAP + CD4 + T cells among the PBMCs was 1.07±0.35% in the HCC post-operative group, which was significantly declined compared with that in the HCC pre-operative group (1.84±0.85; P= 0.021), while it remained slightly, but not significantly higher than that in the control group (0.73±0.39%; P=0.342).
Results
LAP
Histopathological analysis of LAP
+ CD4 + T cells in HCC tissues. As exemplified in the representative image in Fig. 4 , LAP was localized in the cytoplasm and on the cell membrane of CD4 + T cells in HCC tissues. In normal hepatic tissues and peri-cancer tissue, LAP + CD4 + T cells were scattered, but were mostly clustered in tumor stroma and located close to other lymphocytes (Figs. 5-7) . Of note, a large number of LAP + CD4 + T cells were observed in HCC nests (cancer nests have a clear boundary and are primarily composed of heavily stained basal cells. Cancer cells are also well differentiated and nuclear fission is rare) and they were in close contact with CD4 + T cells (Fig. 8) .
As presented in Table II , the average number of LAP + CD4 + T cells per high-power field in the HCC group, peri-cancer group and normal control group was 11.25±3.00, 5.75±1.00 and 2.61±0.83, respectively. The difference in the abundance of LAP + CD4 + T cells was significant between the HCC group and the control group (P= 0.013), between the peri-cancer group and the control group (P= 0.025), and between the peri-cancer group and the HCC group (P=0.018).
Discussion
In 1995, Sakaguchi et al (13) (14) . FOXP3 is the specific transcription factor of Treg cells and is specifically expressed on their surface. It is the most specific surface marker of Treg cells and regulates their development, activation and functions (15) .
LAP was first discovered by Miyazono et al (16) in 1993. It is a pro-peptide that binds non-covalently to the amino terminus of TGF-β. TGF-β is a multifunctional polypeptide growth factor that is usually secreted out of the cells in its inactive or latent precursor form and exerts its biological activity after activation and binding to TGF-β receptor (TβR). Pre-activated complexes of TGF-β include TGF-β homodimer, as well as those with LAP and latent TGF-β binding protein (LTBP). LAP remains connected to TGF-β via a non-covalent bond after being cleaved from TGF-β precursor by a specific protease and forms an inactive complex with LTBP to prevent uncontrolled activation of TβR (17) . In addition to keeping TGF-β in a latent state, LAP also has an important role in releasing and targeting latent TGF-β to the extracellular matrix, whereas LTBP guides the assembly and secretion of latent TGF-β complexes. Activation of TGF-β is achieved by partial or total enzymatic cleavage of LAP (18). In 2001, Nakamura et al (19) reported that TGF-β precursor is expressed in mouse CD4 + T cells, drawing attention to the functions of LAP in CD4 + T cells. Oida et al (20) indicated that CD4 + T cells express LAP on their surface regardless of whether CD25 is expressed. A previous study also suggested that CD25 expression in CD4 + CD25 + Treg cells is closely linked to the regulatory activity of these cells (14) . However, Nakamura et al (21) demonstrated that LAP + T cells with TGF-β1 on their cell surface exert inhibitory effects, which is independent of the expression of CD25. Therefore, they reasoned that LAP as a surface marker of Treg cells has more advantages than CD25. Chen et al (9) + T cells were induced to secrete IL-10 in the joint to inhibit arthritis-specific reactive T-cell proliferation, the generation of specific antibodies and the development of arthritis (23) . Different from the LAP + CD4 + T cells in the mouse model of arthritis, LAP + CD4 + T cells induced in models of systemic lupus erythematosus and diabetes inhibited the development of T helper cells in a TGF-β-dependent manner to alleviate the disease (24, 25) . The above studies not only reveal the generality of immunosuppressive action, but also suggest the differentiation of immunosuppression. For instance, TGF-β mainly works in models of systemic lupus erythematosus, diabetes and encephalomyelitis, high levels of IL-10 are secreted in arthritis models to inhibit effector T cells, and TGF-β and IL-10 work jointly in the colitis model.
Previous studies (9, 19, 22, 23) The present results have demonstrated that the proportion of LAP + CD4 + T cells among the PBMCs of patients with HCC at the post-operative stage was significantly declined compared with that at the pre-operative stage, while it remained slightly but not significantly higher compared with that in the control group. However, the advanced stage of these two patients with metastasis may have affected the results of flow cytometry. This result indicates that radical resection affects the levels of LAP + CD4 + T cells in the peripheral blood of patients with HCC and it balanced out the immunologic derangement, reducing LAP + CD4 + T cells to the normal level. The possible mechanisms include the following: i) In the absence of tumor antigens, the anti-tumor immune response, which mostly comprises cellular immunity, decreases and the inhibitory effect of LAP + CD4 + T cells on the anti-tumor immune + T cells to the normal level. As LAP + CD4 + T cells in the blood of patients with HCC also (partially) originate from the tumor environment itself, where upon they are released into the circulation, it can be hypothesized that these trends may be more marked in hepatic tissues. Due to the difficulty of hepatic tissue sampling from patients with HCC following radical resection, it is difficult to validate this hypothesis. Future studies should therefore determine the difference in LAP + CD4 + T cell expression in hepatic tissue following radical resection in animal models.
The immunity of patients with primary HCC is weak, and the local immune microenvironment of the tumor is abnormal, resulting in failure of immune defense. It is an important factor for the immune evasion, recurrence and metastasis of HCC (29) . A previous study revealed that immunosuppressive Treg cells were abnormally increased in the peripheral blood and tumor tissues of patients with HCC (30) . Therefore, the extent of Treg cell infiltration in tumor tissues is representative of the suppression of anti-tumor immunity and is a key mechanism resulting in tumor immune tolerance and immune escape. In the present study, immunohistochemical staining with double enzyme labeling indicated that i) LAP is located in the cytoplasm and on the membrane of CD4 + cells were present not only in the stroma but at the surface of sinusoids or capillaries. This may be due to the breakage of certain LAP + CD4 + T cells during the preservation and fixation process of the tissue sections, resulting in positive staining in sinusoids and capillaries. Therefore, it may be speculated that LAP + CD4 + T cells are gathered in local tissue of HCC to negatively regulate effector T cells, which then inhibit specific and non-specific anti-tumor immune responses, possibly resulting in changes in the local microenvironment of the tumor in favor of tumor cell proliferation and migration.
Treg cells mediate the immune evasion of tumors via multiple molecular mechanisms. At present, the immune regulation effects of Treg cells and the underlying mechanisms have remained to be fully elucidated. An in vitro study indicated that CD4 + CD25 + Treg cells may mediate immunosuppression by cell-to-cell contact-dependent and cytokine-independent mechanisms, whereas the subsequent in vivo study indicates that a cytokine-dependent mechanism may also exist. For instance, IL-10 has an important role in immune inhibition and TGF-β may participate in this process (32) . Studies on animal models with autoimmune diseases and inflammation indicated that LAP + CD4 + T cells exert their immunosuppressive activity by inhibiting effector T cells (23, 24) . At present, little is known regarding LAP + CD4 + T cells in the tumor microenvironment. The present study indicated that in HCC tissues, LAP + CD4 + T cells are mostly clustered and localize close to lymphocytes; In the present study, the distribution of LAP + CD4 + T cells in patients with HCC with different grades of differentiation and clinical stages was not analyzed due to the limited funding and the number of cases included; this will be investigated in a future study by our group. Elucidation of the functions of LAP + CD4 + T cells in the tumor microenvironment and the underlying regulatory mechanisms, as well as identification of methods to regulate LAP + CD4 + T-cell proliferation, may lead to the development of more effective anti-tumor immunotherapies.
